Figures computed from official regulatory filings — .
Analysttarget 12 USD (+143%)
Ownershipinsiders 26.33% · institutions 48.71% · short 1.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CHAMPIONS ONCOLOGY, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
93 buys13 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Brainin Robert Lawrence | AwardD (derivative) | $1.8M | Unusual size |
| Brainin Robert Lawrence | AwardD (derivative) | $780K | Unusual size | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $106.9K | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $100K | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $98.9K | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $780K | Unusual size | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $105.1K | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $487.5K | Unusual size | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $487.5K | Unusual size | SEC |
| Brainin Robert Lawrence | AwardD (derivative) | $1.2M | Unusual size | SEC |
| ACKERMAN JOELtrack record | AwardD (derivative) | $144.3K | SEC |
| SIDRANSKY DAVIDtrack record | AwardD (derivative) | $144.3K | Unusual size | SEC |
| TOBIN SCOTT R | AwardD (derivative) | $173.1K | SEC |
| Mendelson Daniel Newmantrack record | AwardD (derivative) | $93.8K | SEC |
| Breitfeld Philip P. | AwardD (derivative) | $93.8K | SEC |
| ACKERMAN JOELtrack record | ExerciseD (derivative) | $198.3K | SEC |
| ACKERMAN JOELtrack record | Exercise | $198.3K | SEC |
| Breitfeld Philip P. | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Breitfeld Philip P. | AwardD (derivative) | $86.8K | SEC |
| SIDRANSKY DAVIDtrack record | AwardD (derivative) | $101.5K | SEC |
| ACKERMAN JOELtrack record | AwardD (derivative) | $200.4K | Unusual size | SEC |
| TOBIN SCOTT R | AwardD (derivative) | $160.3K | SEC |
| Mendelson Daniel Newmantrack record | AwardD (derivative) | $100.2K | SEC |
| ACKERMAN JOELtrack record | ExerciseD (derivative) | $90.5K | SEC |
| ACKERMAN JOELtrack record | Exercise | $90.5K | SEC |